. Net clinical benefit of LAAC compared with warfarin therapy over time in the artificially lower PE incidence scenario. Lowered PE incidence: scenario where the PE incidence is artificially lower to 1% from 3%. mRS score for ischemic and hemorrhagic stroke are used and fixed weights for major bleed and pericardial effusion of 0.05. Figure S2 . Absolute risk difference using mRS weights for ischemic and hemorrhagic stroke and fix weights of 0.10 for major bleed and pericardial effusion events. Figure S3 . Absolute risk difference using mRS weights for ischemic and hemorrhagic stroke and fix weights of 0.15 for major bleed and pericardial effusion events.
